IPO in Chinese Mainland Stock Markets

• Innovita Biological Technology Co., Ltd. (688253.SH) IPO on SSE STAR Market (2022)

• Dizal Pharmaceutical Co., Ltd. (688192.SH) IPO on SSE STAR Market (2021)

• GalaxyCore, Inc. (688728.SH) IPO on SSE STAR Market (2021)

• Beijing Novogene Co., Ltd. (688315.SH) IPO on SSE STAR Market (2021)

• Ninebot Limited (689009.SH) IPO on SSE STAR Market (2020).  This is the first case that a red-chip company offers CDR to be listed on Chinese stock markets.

• Taiho Photoelectricity Co. Ltd. (603656.SH) IPO on SSE Main Board (2017)

• Jiangsu Riying Electronics Co., Ltd. (603286.SH) IPO on SSE Main Board (2017)

IPO in Hong Kong & Overseas Stock Markets

• Biocytogen Pharmaceuticals (Beijing) Co., Ltd. IPO on the Main Board of HKEX (2022) 

• Jiangsu Recbio Technology Co., Ltd. (02179.HK) IPO on the Main Board of HKEX (2022)

• Nano Labs Limited (NA) IPO on NASDAQ (2022)

• SenseTime Group Inc. (0020.HK) IPO on the Main Board of HKEX (2021)

• Antengene Corporation Limited (06996.HK) IPO on the Main Board of HKEX (2020)

• Canaan Inc. (CAN) IPO on NASDAQ (2019)

• Ascentage Pharma (6855.HK) IPO on the Main Board of HKEX (2019)

M&A and Major Assets Reorganization

• Acquisition of Le Belier (251 million Euro) by Guangdong Wencan (Stock Code: 603348.SH) (2020)

• Acquisition of Cloos Group by Nanjing Estun (Stock Code: 002747.SZ) (2020)

• Acquisition of Krauss Maffei Group by Qingdao Tianhua Institute (Stock Code: 600579.SH) (a subsidiary of ChemChina) (2019)

• Strategic Cooperation of Barrick Gold and Shandong Gold Mining (Stock Code: 600574.SH) By Shandong Gold Mining’s Acquisition of 50% of Valadero Gold for 960 million USD (2018)

• China Cinda Asset Management Co. and Hainan Airlines to Form Acquisition Fund (10 billion RMB) to Acquire Gategroup (2017)

• Acquisition of Super Sports Media  by China Cinda Asset Management Co. and DDMC Group (600547.SH) (2017)

• Acquisition of Biejing Liujie by Jiaxun (Stock Code:300213)(2017)

Equity Investment and Financing

• Represented The Carlyle Group for its D Round Investment Into Abbisko Therapeutics Co., Ltd.

• Represented The Greater Bay Area Homeland Investment Fund for its C Round Investment Into Elpiscience Biopharma, Ltd.

• Represented The PICC Equity Investment Fund for its B Round Investment Into Abogen Bio.

• Represented Beijing Menlo Biotech Company for its VIE Set-up and Restructuring

• Represented Haitong Capital, Efung Capital and Huarong Rongde for their B Round Investment Into Jiangsu Gensciences 

• Represented BioTrack Capital for its A+ Round Investment Into Guangzhou Reforgene Medicine

• Represented BioTrack Capital for its B+ Round Investment Into Beijing EdiGene Biotech Company

• Represented Beijing Changmugu Medical Technology Co., Ltd. For its B round financing and B+ round financing

• Represented Forecyte Bio for it’s a round financing

• Represented APRINOIA Therapeutics for its ESOP

• Represented Rinua Gene for its Establishment and Series Seed Round financing

• Represented Rinua Gene for its VIE Set-up and Restructuring

• Represented CMG-SDIC Capital for its B Round Investment Into Inceptio Technology Company

• Represented Sequoia for its A+ Round Investment Into Orka Inc.

• Represented CMG-SDIC Capital for its A Round Investment Into Suzhou Porton Advanced Solutions

• Represented Asymchem Biotech Investment Fund, Suzhou Ribo Life Science Co., Ltd. and Asymchem to Found an API CMO Joint Venture

• Represented Gyee Capital for its D Round Investment Into SceneRay Medical Device Company

• Represented Lapam Capital for its A+ Round Investment Into Shanton Pharma Holdings Limited

• Represented Hongtai Aplus for its B Round Investment Into CGeneTech (Suzhou) Co., Ltd.

• Represented Huagai Capital for its B Round Investment Into Immvira Bioscience Inc.

• Represented Starquest Capital for its C Round and D Round Investment into Miaoshou.net

• SDIC Fund, Chinalifepe, Ping’an and Taikang 260 million USD Series D Investment in Innovent (Red-Chip Structure)

• CIIFUND Investment in Kuaishou Technology (Red-Chip Structure)

• SDIC Fund Series B Investment in Ascentage Pharma

• Huagai Capital Investment in Shanghai Haihe Parma (Red-Chip Structure)

• Antengene Corporation Red-Chip Restructure and Series B Financing (Red-Chip Structure)  

• Antengene Corporation Series C Financing (Red-Chip Structure)

• Huagai Capital Series B Investment in Immvira 

• Exegenesis Series B and B+ Financing (Red-Chip Structure)

• Antengene Corporation ESOP Project

• New Horizon Fund Investment in Connect Biopharma (Red-Chip Structure)

• New Alliance Capital Investment in CF Pharmtech

• Taikang Insurance investment in Viva Biotech

• SDIC Fund and AstraZeneca Joint Venture of Dizal Jiangsu

• Dizal Jiangsu Series A Financing

• SDIC Fund Investment in Bright-Gene

• CMG-SDIC Capital  Investment in Omni Pharma (Red-Chip Structure)

• Lapam Capital Investment in Surefire Medical,Inc.

• SDIC Fund Investment in Novogene

• China Life PE Investment in Soyoung (On-line Commerce of Aesthetic Medicine)

• Starquest Capital Series C and D Investment in Miaoshou.com (On-line OTC and Internet Hospital)

• Lapam Capital Investment in Asieris Pharmaceuticals

• CMS China Investment in Kingsoft Cloud (Red-Chip Structure)

• CMS China Investment in To8To.com (Red-Chip Structure)

• CMS China Investment in Qing Cloud (Red-Chip Structure)

• China Merchants Jintai Capital Investment in Mobike (Red-Chip Structure)

• China Merchants Jintai Capital Investment in Meituan.com (Red-Chip Structure)

• China MobileFund Management Investment in Liepin.com (Red-Chip Structure)